A prospective national study of the safety of immunotherapy
- 1 January 1980
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 10 (1), 59-64
- https://doi.org/10.1111/j.1365-2222.1980.tb02080.x
Abstract
A prospective study was made in France to determine the frequency, nature, causes and consequences of systemic reactions occurring during specific immunotherapy. One hundred and fifty five reactions were recorded in 151, 997, injections given to 19,739 patients; a percentage of 0.1. It was higher with pollen extracts (0.2%) and practically nil with other extracts (house dust, Dermatophagoides, insect body, bacteria). Asthma, spasmodic rhinitis and urticaria were the most frequent, 80% of systemic reactions. In 59% no explanation could be found. The main known causes of adverse reactions were excessive doses of antigen, improper timing of treatment or incorrect technique of injection. After appropriate treatment the immunotherapy was continued in nearly 90% of the cases. Specific immunotherapy with the majority of extracts now being used, namely adsorbed extracts, is not dangerous but it must be precisely and cautiously done because errors are responsible for nearly 50% of the recorded systemic reactions.This publication has 8 references indexed in Scilit:
- A Review of ImmunotherapyAllergy, 1978
- The safety of immunotherapy during pregnancyJournal of Allergy and Clinical Immunology, 1978
- Stability of antigen E in commercially prepared ragweed pollen extractsJournal of Allergy and Clinical Immunology, 1974
- Adverse reactions to injected emulsified pollen extract in allergic patients on the west coast: Relationship to the total dosage of antigenJournal of Allergy, 1961
- Reciprocal influences of bronchial asthma and pregnancyAmerican Journal Of Medicine, 1946
- Studies in Specific HypersensitivenessThe Journal of Immunology, 1922
- FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE.The Lancet, 1911